Bristol Myers Squibb and Pfizer will offer Eliquis through Mark Cuban Cost Plus Drug Company, expanding access for cash-paying patients.
Beginning April 27, patients with a prescription can purchase a 30-day supply of the drug on CostPlusDrugs.com for $345, according to an April 24 news release. The collaboration adds one of the most widely prescribed oral anticoagulants in the U.S. to the platform.
Eliquis is used to reduce the risk of stroke and blood clots in patients with atrial fibrillation and to treat and prevent deep vein thrombosis and pulmonary embolism.
The deal builds on Cost Plus Drugs’ broader push to expand beyond generics into branded drugs and partnerships across manufacturing and distribution. In the last year, the company has expanded its network of pharmacy benefit manager partnerships, grown its affiliate pharmacy network and increased transparency efforts, including posting contracts and pricing structures publicly.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.